SAN DIEGO, Nov. 08, 2017 — Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that the company will participate in the Stifel 2017 Healthcare Conference in New York, NY.
The Company will be presenting at 9:30 AM Eastern on Wednesday, November 15, 2017. A live webcast of the presentation will be available on the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/. An archive of the presentation will be available for replay following the conference.About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.Contact:
Vital Therapies, Inc.
Vice President, Investor Relations and Business Development
Latest posts by Sarah Thompson (see all)
- Dolby Brings Dolby Atmos Immersive Sound on SamsungÂ Mobile Devices - February 25, 2018
- GIAPREZAâ„¢ (angiotensin II) Significantly Improved Survival of Patients with High APACHE II Scores in ATHOS-3 Study - February 25, 2018
- Hipo a Revolutionary Device for Alzheimer's by Mosaikx - February 25, 2018